Somatostatin Analogs Market Report 2026

The somatostatin analogs market size has grown strongly in recent years. It will grow from $7.16 billion in 2025 to $7.66 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to neuroendocrine tumor diagnosis growth, hormone disorder prevalence, clinical efficacy evidence, specialist prescribing, hospital access.

The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to $10.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to biosimilar launches, expanded indications, aging population growth, improved diagnosis rates, specialty drug reimbursement. Major trends in the forecast period include growth of long-acting injectables, expanded neuroendocrine tumor indications, improved patient compliance focus, biosimilar development, hospital-based therapy growth.

The growing aging population is expected to drive the growth of the somatostatin analogs market in the coming years. The aging population refers to a demographic trend marked by an increasing number or higher proportion of individuals aged 65 years and older in a society. The rise in this demographic is associated with a higher prevalence of diseases that require the use of somatostatin analogs, thereby boosting demand for these pharmaceuticals. For example, according to the UK Parliament's House of Commons Library, a UK-based government body, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to reach 22.1 million by 2072, accounting for 27% of the population. Therefore, the growing aging population is driving the expansion of the somatostatin analogs market.

Key players in the somatostatin analogs market are focusing on developing advanced products, such as targeted radiopharmaceuticals, to improve the precision and effectiveness of cancer treatments, particularly for patients with somatostatin receptor-positive tumors. Targeted radiopharmaceuticals are specialized drugs that combine radiation-emitting isotopes with molecules designed to bind specifically to cancer cells, enabling precise delivery of therapeutic radiation to tumor sites while minimizing exposure to healthy tissues. For instance, in January 2024, Lantheus, a US-based radiopharmaceutical company, launched Lutetium Lu 177 Dotatate. Lutetium Lu 177 Dotatate is a radiolabeled somatostatin analog used in peptide receptor radionuclide therapy (PRRT) for treating advanced somatostatin receptor-positive neuroendocrine tumors. Clinical studies have shown that it significantly improves progression-free survival and response rates compared to traditional somatostatin analogs like octreotide, making it an important option for patients whose disease has progressed despite prior treatments. Its targeted mechanism allows effective tumor control while reducing systemic exposure, enhancing the overall therapeutic profile for managing neuroendocrine malignancies.

In October 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, collaborated with Philogen S.p.A. to strengthen its portfolio and expand access to innovative cancer therapies. Through this collaboration, Sun Pharmaceutical aims to enhance its product portfolio, broaden access to innovative cancer treatments, and commercialize the under-development skin cancer drug Nidlegy in Europe, Australia, and New Zealand. Philogen S.p.A. is an Italy-based biotechnology company specializing in the development of targeted therapeutics for oncology.

Major companies operating in the somatostatin analogs market are Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH.

North America was the largest region in the global somatostatin analogs treatment market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatostatin analogs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the somatostatin analogs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the somatostatin analogs market by increasing costs for imported APIs, injectable formulations, and pharmaceutical packaging. Hospitals and pharmaceutical companies in Asia-Pacific and Europe are most affected due to international sourcing of octreotide, lanreotide, and pasireotide. These cost pressures can increase treatment expenses for neuroendocrine and hormonal disorders. However, tariffs are encouraging domestic drug formulation and generic production, supporting long-term market stability.

The somatostatin analogs market research report is one of a series of new reports that provides somatostatin analogs market statistics, including somatostatin analogs industry global market size, regional shares, competitors with a somatostatin analogs market share, detailed somatostatin analogs market segments, market trends and opportunities, and any further data you may need to thrive in the somatostatin analogs industry. This somatostatin analogs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A somatostatin analog is a synthetic form of somatostatin that slows the production of hormones, such as growth hormone and serotonin. It is used to alleviate symptoms of carcinoid syndrome, including diarrhea and skin flushing.

The main types of somatostatin analogs include octreotide, lanreotide, and pasireotide. Octreotide is a medication that inhibits growth hormones in a manner similar to natural somatostatin and is used to treat certain types of tumor-related diarrhea and flushing. These analogs are applied in conditions such as acromegaly, Cushing’s syndrome, neuroendocrine tumors, carcinoid syndrome, and others, and are utilized by end users including hospitals and pharmaceutical companies.

The somatostatin analogs market consists of sales of sandostatin, sandostatin lar, olatuton, somatuline LA, and somatuline autogel. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.